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Background. Adrenomedullin, is a potent vasorelaxant that is
highly expressed in the adrenal medulla, kidney, heart and lung.
Since there is indirect evidence that hypervolemia enhances the
release of this peptide, we measured plasma adrenomedullin in 9
uremic patients on chronic dialysis treatment and in 10 healthy
subjects matched for age and gender.
Methods. Measurements were performed in baseline conditions,
after isotonic fluid subtraction (by isolated ultrafiltration) and
during a 70° tilt. Tilt was performed in volume-depleted state, that
is, after isolated ultrafiltration (UF). In the control experiment
patients underwent sham UF (UF 5 0) followed by a period of
supine resting identical to the one they had spent in tilted position
in the active experiment. Adrenomedullin was measured on
pre-extracted plasma samples (Sep-Pak C-18 cartridges) by a
specific RIA for human adrenomedullin 1-52.
Results. The average plasma adrenomedullin was 2.6 times
higher (P , 0.01) in uremic patients (103 6 8 pg/ml) than in
healthy subjects (39 6 7 pg/ml). After fluid subtraction (22.6 6
0.2 liter) adrenomedullin fell to 79. 6 8 pg/ml (P 5 0.02) but
remained well above the upper limit of the 95% CI in normal
subjects (52 pg/ml). There was no relationship between ad-
renomedullin and ANF changes. In the control experiment sham
UF did not modify plasma adrenomedullin. Tilt did not signifi-
cantly change plasma adrenomedullin either in dialysis patients or
healthy subjects.
Conclusions. Plasma adrenomedullin is markedly raised in
uremic patients on dialysis, which confirms that the kidney has a
major role in the clearance of this peptide. However, the fall in
plasma adrenomedullin after isolated UF indicates that the
plasma concentration of this peptide is influenced by the body
fluid volume status. Whether or not adrenomedullin participates
in the counter-regulatory response to fluid subtraction in uremic
patients remains to be explored by specific antagonists of this
substance.
Adrenomedullin is a 52 amino acid polypeptide isolated
from human pheocromocytoma that is structurally homol-
ogous to calcitonin gene-related peptide (CGRP) [1]. Like
CGRP, adrenomedullin is a potent vasorelaxant, and there
is increasing evidence that this peptide may function as a
paracrine and/or autocrine factor in the regulation of
cardiovascular homeostasis [2–4]. Adrenomedullin is mea-
surable in human plasma [5] and it has been found that the
concentration of this substance is raised in clinical situa-
tions associated with altered extracellular volume control
such as heart failure [6–14], chronic renal failure [14–18],
hypertension [15, 18, 19] and primary hyperaldosteronism
[20]. Circulating adrenomedullin is markedly raised in
hemodialysis patients [16, 17], a phenomenon that has been
attributed to reduced renal clearance of this peptide [17].
Extracellular volume undergoes cyclical changes in ure-
mic patients on chronic hemodialysis, increasing gradually
during the dialysis interval and decreasing rapidly during
ultrafiltration-dialysis. Measuring the influence of volume
stimuli on plasma adrenomedullin may provide useful
information on the regulation of circulating levels of this
peptide in dialysis patients. Therefore, in this study we
sought to establish whether extracellular fluid volume
removal by isolated ultrafiltration and tilt-induced central
hypovolemia has a measurable influence on plasma ad-
renomedullin concentration in these patients.
METHODS
Patients
Nine uremic patients (6 males and 3 females; age 52 6 14
years, mean 6 SD) on regular dialysis treatment partici-
pated in the study. They had been on treatment for periods
ranging from 1 to 16 years (5.5 6 3.4, mean 6 SD). All were
being dialyzed by cuprophan filters by using a standard
dialysate (Na 145 mmol/liter, K 1.5 mmol/liter, HCO3 37
mmol/liter, Ca 1.50 to 1.75 mmol/liter, Mg 0.5 mmol/liter).
Their Kt/Vs ranged from 1 to 1.6. Causes of renal failure
were polycystic renal disease in three, rapidly progressing
glomerulonephritis in one, chronic pyelonephritis in one,
cortical necrosis in one, and undefined in three. Residual
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renal function was negligible in all but one case (24 hr urine
volume 500 ml). Four patients had mild to moderate left
ventricular hypertrophy on echocardiography, but none
had evidence of heart failure. All patients were judged to
be at “dry weight” by standard clinical criteria [21]. Three
patients were on antihypertensive treatment (Nifedipine
slow release), and in these cases drug treatment was
withdrawn at least one week before the study.
The control group was formed by 10 healthy, normoten-
sive subjects (7 males and 3 females, mean age 47 6 10
years, 6 SD, range 23 to 55 years) recruited from the
medical and nursing staff.
Study protocol
The protocol of the study was in conformity with the
ethical guidelines of our institution, and informed consent
was obtained from each participant. Both the active and
control experiments (see below) were performed midweek,
after a short dialysis interval.
Dialysis patients
Active experiment. On the day of study, patients had their
blood pressures and heart rates monitored at three minute
intervals for 30 minutes while resting in supine position on
a dialysis bed equipped with a scale. Baseline blood sam-
pling was performed at the end of this period. Then
isolated ultrafiltration [22] was started at a rate of about 20
ml/min. During this procedure no dialysate circulated
through the filter and the ultrafiltrate was collected in a
graduated cylinder. Ultrafiltration was interrupted when all
the body wt excess accumulated during the preceding
dialysis interval was removed. Blood sampling was per-
formed again at the end of ultrafiltration. Arterial pressure
and heart rate were measured three times with a three
minute interval before sampling. Isolated ultrafiltration was
followed by 180 minutes of isovolumic dialysis (with a
standard dialysate, see above). Immediately after dialysis
the response to tilting was tested. Tilting was carried out
with patient lying on a motor-driven tilt table angled at 70°.
Arterial pressures and heart rates were measured every two
minutes while the final blood sample was taken either after
14 minutes or, if signs of intolerance to the maneuver had
supervened, immediately before returning the patients to
the supine position.
Control experiment. In the control experiment the inlet
and the outlet of the dialysate compartment were accu-
rately sealed to avoid ultrafiltration while the blood circu-
lated through the filter (sham ultrafiltration). After sham
ultrafiltration (which, case by case, lasted exactly as long as
the isolated ultrafiltration in the active experiment), dialysis
was carried out for 180 minutes. At the end of the dialysis
session, patients remained in bed in a supine position for
the same time they had been in a tilting position in the
active experiment. Blood sampling was performed at the
same time points as the active experiment.
Healthy subjects
Healthy subjects had their blood pressures and heart
rates monitored at three minute intervals for 30 minutes
while resting in a supine position with blood sampling at the
end of this period. Tilting was then performed. Arterial
pressure measurements and blood sampling were repeated
after 1, 10 and 30 minutes of tilting.
Methods
Plasma cathecolamines and plasma renin activity (PRA)
were measured by commercially available RIA methods
(Amicyl-testy; Immunological Laboratories, Hamburg,
Germany; and Renctky, Sorin, Vercelli, Italy). Atrial na-
triuretic factor (ANF) and endothelin I were measured on
pre-extracted plasma samples according to methods estab-
lished in our laboratory [23, 24]. Plasma adrenomedullin
was measured on pre-extracted (C-18 Sep-pak) plasma
samples by a sensitive RIA employing an antibody against
human adrenomedullin (Peninsula Laboratories, Mersey-
side, UK). This antibody does not cross react with human
CGRP, endothelin I, ANP, BNP and CNP. All ad-
renomedullin plasma samples were processed in a single
assay and the intra-assay variation of this RIA in our
laboratory was 7%. Reverse-phase HPLC studies showed
that plasma immunoreactive adrenomedullin emerged as a
single peak at a position identical to that of authentic
human adrenomedullin (1-52) in uremic subjects [16].
Furthermore, studies in our laboratory had also shown that
the loss of peptide hormones with molecular weight ex-
ceeding 1000 Daltons (adrenomedullin molecular wt 5
6,028) was negligible during isolated ultrafiltration per-
formed by cuprophan filters [25].
Arterial pressure and heart rate measurements were
performed by an automatic sphygmomanometer connected
to an automatic recorder (Dinamap, model 1540; Critikon,
Tampa, FL, USA).
Data analysis
Baseline arterial pressure and heart rate represent the
average value of the last three measurements recorded
during the supine rest. In dialysis patients, the average
value of the three blood pressure and heart rate recordings
(before blood sampling) at the end of isolated ultrafiltra-
tion and the measurement at the end of tilting (again,
immediately before blood sampling) were considered for
statistical analysis. In healthy subjects during the tilting
procedure the hemodynamic measurements preceding each
blood sampling were taken.
Biochemical measurements were corrected for hemocon-
centration by multiplying each measurement by the Prb/Prx
ratio, where Prb represents the serum proteins concentra-
tion of the baseline sample and Prx the concentration of the
sample.
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Data are presented as mean 6 SEM. The response to tilt
in healthy subjects was analyzed by one way ANOVA
followed by the Newman Keuls test for multiple compari-
sons. Because in dialysis patients we planned two sets of
paired comparisons (paired t-tests for baseline vs. post-
ultrafiltration and pre-tilt vs. post-tilt), we considered only
differences with P , 0.025 (Bonferroni inequality) to be
statistically significant. The relationship between paired
variables was tested by the least squares method.
RESULTS
Baseline plasma adrenomedullin was 2.6 times higher
(P , 0.01) in uremic patients (103 6 8 pg/ml) than in
healthy subjects (39 6 7 pg/ml). In both groups ad-
renomedullin was independent of age, arterial pressure and
heart rate.
Adrenomedullin in dialysis patients
Active experiment: Isolated ultrafiltration (Table 1 and Fig.
1). No patient had syncopal episodes or vomited during the
procedure. The volume of ultrafiltrate removed ranged
from 1.8 to 3.5 liters (average 2.6 6 0.2 liter), which
produced a 34% increase in serum proteins concentration.
Mean arterial pressure fell significantly (P , 0.01) during
UF while the heart rate showed a small rise (NS). Plasma
norepinephrine, PRA and plasma antidiuretic hormone
(ADH) rose significantly (P , 0.01) while ANF changed in
the opposite direction (NS). Plasma endothelin was little
affected by UF. As shown in Figure 1A, plasma ad-
renomedullin concentration decreased significantly after
UF (from 103 6 9 pg/ml to 79 6 8 pg/ml, P , 0.02), the
average decrease being 20% 6 7% (range 0.7% to 235%),
but on average it remained at levels 1.5 higher than the
upper limit of the 95% CI in healthy subjects (52 pg/ml).
Changes in plasma adrenomedullin and ANF were much
more pronounced after correction of the data for hemocon-
centration (Table 1). The fall in plasma adrenomedullin
was unrelated to changes in mean arterial pressure, plasma
norepinephrine (r 5 20.32), PRA (r 5 20.06), ANF (r 5
0.0), endothelin (r 5 0.0) and ADH (r 5 0.67, P 5 0.068).
Active experiment: Tilt. Only five patients were able to
maintain the tilt position longer than 10 minutes. The
average tilt tolerance was 7.8 6 1.8 minutes (range 1 to 14
min). Tilt caused an 8 mm Hg fall in MAP associated with
a significant rise in heart rate and in plasma catecholamines
(Table 1). PRA, plasma Endothelin and plasma ANF were
unaffected by tilt. Plasma adrenomedullin after tilt fell in
all but three patients (pre-tilt 98 6 7, tilt 84 6 11), but on
average these changes failed to attain the threshold of
statistical significance (Fig. 1B).
Control experiment. There were no significant changes in
plasma adrenomedullin either after sham UF or bed resting
(for a period identical to that spent in tilt position in the
active experiment; Table 2). Adrenomedullin changes dur-
ing sham UF were significantly less pronounced than
during active UF (P 5 0.02). During sham ultrafiltration
there was a significant increase in plasma catecholamines
(P , 0.01), an expected effect of extracorporeal blood
cooling [26, 27].
Healthy subjects
Response to tilt. Mean arterial pressure was well main-
tained during early tilt and showed a 8 mm Hg decrease at
the end of the test while the mean heart rate showed an
immediate and steady increase (P , 0.01; Table 3 and Fig.
2). Plasma norepinephrine (P , 0.01) and PRA (P 5 0.048,
NS) displayed the expected rise. Plasma adrenomedullin
was affected very little by tilt (one way ANOVA, P 5 0.56).
Fig. 1. In the active experiment, the changes in
plasma adrenomedullin concentrations induced
by isolated ultrafiltration (A) and by tilt (B).
The dotted line indicates the upper limit of the
95% CI in healthy subjects (52 pg/ml).
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By the same token, plasma ANF remained by-and-large
unchanged.
DISCUSSION
The main finding in this study is that in dialysis patients,
the raised plasma adrenomedullin concentration depends
in part on the extracellular volume expansion generated
during the dialysis interval.
Adrenomedullin is a potent vasodilator that is highly
expressed in the cardiovascular system (cardiac myocytes,
endothelial and vascular smooth cells), the adrenal me-
dulla, lung and kidney. There are several lines of evidence
suggesting that this vasodilator is involved in cardiovascular
and extracellular volume control. Injected intrarenally in
the dog it has a clear-cut natriuretic effect [28], during high
salt diets it is more intensely expressed in the ventricle of
salt sensitive than in Dahl resistant rats [29], and it is
actively secreted by the human heart [9]. The regulation of
adrenomedullin production is complex because it is influ-
enced by circulating hormones and growth factors [30, 31]
as well as by cytokines, IL-1a, TNF and lipopolysaccaride,
which additively stimulate its synthesis [32]. The plasma
half-life of adrenomedullin is about 20 minutes [33] and
most likely the kidney as well as the lungs are important
sites of adrenomedullin clearance. Because the plasma
concentration of this substance and of the related com-
pound, proadrenomedullin N-terminal 20 peptide (PAMP)
[34], is strictly related to creatinine clearance, reduced
renal extraction is considered to be the main determinant
of the high plasma concentration in patients with chronic
renal failure [14–18], particularly in hemodialysis patients
[16, 17] where adrenomedullin is poorly removed by dialy-
sis treatment [17]. The influence of isotonic fluid removal
(by isolated ultrafiltration) on plasma adrenomedullin in
dialysis patients has not been investigated.
Extracellular volume subtraction by isolated ultrafiltra-
tion has been often applied to study the influence of body
fluid volume status on cardiovascular hormonal factors in
dialysis patients [23, 25, 35, 36]. We felt that this procedure
required an appropriate control study because changes in
plasma concentration during ultrafiltration may be influ-
enced by adsorption phenomena, by the generation of
cytokines promoted by the contact of the blood with the
cuprophan membrane (see above) [32], and by extracorpo-
real blood cooling [26, 27]. To circumvent this problem we
performed a control study including sham ultrafiltration.
The fact that adrenomedullin showed a clear-cut reduction
after isolated ultrafiltration while it remained unchanged
after sham ultrafiltration clearly indicates that the body
fluid volume status per se has an independent effect on the
plasma concentration of this peptide. It should be noted
Table 1. Hemodynamic and metabolic measurements in the active




MAP mm Hg 95 6 7 75 6 7a 82 6 7 68 6 7b
Heart rate beats/min 79 6 2 81 6 3 89 6 3 105 6 4a
Total proteins g/dl 6.6 6 0.2 9.0 6 0.3a 8.4 6 0.3 8.6 6 0.3
BUN mg/dl 136 6 3 117 6 14 64 6 4 64 6 4
Adrenomedullin pg/ml 103 6 9 79 6 8b 98 6 7 84 6 11
(corrected for
hemoconcentration)
(58 6 7)a (77 6 5) (67 6 10)
ANF pg/ml 95 6 15 90 6 13 82 6 9 82 6 7
(corrected for
hemoconcentration)
(65 6 10a) (76 6 8) (81 6 6)
PRA ng/ml/h 8.1 6 2.0 25.3 6 9.8a 28.9 6 12.2 30.1 6 11.7
Norepinephrine pg/ml 324 6 37 825 6 82a 529 6 68 903 6 115a
Epinephrine pg/ml 26 6 4 74 6 16b 41 6 11 97 6 20a
ADH pg/ml 4.1 6 0.3 17.8 6 6.1a 5.3 6 0.8 18.6 6 5.7a
Endothelin pg/ml 15.1 6 1.5 15.6 6 1.8 16.8 6 1.3 15.8 6 1.3
Data are mean 6 SEM. Abbreviations are: UF, ultrafiltration; HD,
hemodialysis; MAP, mean arterial pressure; BUN, blood urea nitrogen;
ANF, atrial natriuretic peptide; PRA, plasma renin activity; ADH, anti-
diuretic hormone.
a P , 0.01 and b P , 0.025 (Ultrafiltration vs. Baseline and Tilt vs.
pre-Tilt)




MAP mm Hg 97 6 5 90 6 6 91 6 5 93 6 5
Heart rate
beats min
75 6 4 73 6 4 85 6 4 85 6 3
BUN mg/dl 144 6 16 145 6 15 66 6 8 67 6 8
Total proteins
g/dl
7.2 6 0.2 6.9 6 0.2 6.8 6 0.2 7.0 6 0.2
Adrenomedullin 103 6 18 101 6 18 91 6 19 94 6 39
PRA ng/ml/h 3.1 6 0.9 4.2 6 1.1 4.1 6 1.3 3.9 6 1.1
Norepinephrine
pg/ml
501 6 0.91 645 6 88a 529 6 87 539 6 65
Epinephrine
pg/ml
19 6 4 34 6 6a 28 6 5 43 6 10
Endothelin
pg/ml
11.1 6 1.2 10.6 6 1.2 10.2 6 1.0 9.9 6 0.9
ADH pg/ml 2.3 6 0.4 2.0 6 0.2 2.0 6 0.4 1.7 6 0.4
In this study patients underwent sham ultrafiltration followed by
isovolumic hemodialysis, and then remained supine in the dialysis bed for
a period identical to that of the tilt study (methods section). Data are
mean 6 SEM.
a P , 0.01 vs. baseline
Abbreviations are in Table 1.
Table 3. Hemodynamic and neurohumoral response to tilt in healthy
subjects
Baseline Tilt 1 min Tilt 10 min Tilt 30 min
MAP mm Hg 89 6 3 94 6 3 92 6 3 81 6 6
Heart rate beats/min 63 6 3 75 6 4 78 6 4 77 6 3a
Adrenomedullin pg/ml 39 6 7 48 6 4 49 6 6 46 6 6
PRA ng/ml/h 0.9 6 0.2 0.9 6 0.2 1.7 6 0.7 3.1 6 1.9
Norepinephrine pg/ml 175 6 21 218 6 28 232 6 29 291 6 24a
Epinephrine pg/ml 23 6 7 31 6 7 34 6 7 45 6 5a
ANF pg/ml 13 6 1 12 6 1 10 6 2 10 6 1
ADH pg/ml 7 6 2 3 6 0.3 6 6 1 20 6 11a
Endothelin pg/ml 0.7 6 0.1 0.6 6 0.1 0.6 6 0.1 0.8 6 0.1
Abbreviations are in Table 1.
a P , 0.01 vs. baseline
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that changes in plasma concentration are likely to under-
estimate the reduction in adrenomedullin release elicited
by acute volume subtraction. Indeed, ultrafiltration causes
an important degree of hemoconcentration that tends to
attenuate the fall in plasma adrenomedullin levels. The
influence of fluid subtraction on plasma adrenomedullin
was much more profound when the data were corrected for
hemoconcentration (Table 2). Yet, plasma adrenomedullin
after ultrafiltration remained at higher than normal levels,
suggesting that reduced renal clearance has a major role in
determining high plasma adrenomedullin in dialysis pa-
tients.
There is evidence in humans that adrenomedullin, like
ANF, is directly secreted by the left ventricle and that its
plasma concentration is related to left ventricular end
diastolic pressure in patients with heart failure [9]. Thus,
the heart may be an important source of adrenomedullin in
dialysis patients. We have been careful in excluding from
the study those patients with heart failure or with obvious
fluid overload. The fluid excess in our patients was just the
normal fluid excess that the typical dialysis patient accumu-
lates between two midweek dialyses. If the heart is a source
of adrenomedullin in dialysis patients, then the relationship
between this substance and intracardiac pressures also
must be evident in the normal-high range of intracardiac
pressures, that is, in the range found in these patients
before dialysis [37]. In the present study the effect of
ultrafiltration on plasma adrenomedullin was higher than
that on plasma ANF and there was no relationship between
these two vasodilators. This phenomenon indicates that,
like in a rat model of heart failure [12] where the lung may
be another site for increased adrenomedullin release, the
control mechanism(s) of these two peptides are differently
regulated in uremic humans.
While fluid removal produced a well defined reduction in
plasma adrenomedullin, central hypovolemia by tilt had a
much less strong (and statistically unsignificant) influence.
To our knowledge this is the first study to test the effect of
tilt on plasma adrenomedullin. The fact that this maneuver
did not produce changes in the circulating levels of this
peptide in normal subjects nor potentiated the effect of
ultrafiltration in dialysis patients suggests that central hy-
povolemia is an inadequate stimulus to switch off the
release of adrenomedullin. However, it should be recog-
nized that in dialysis patients the short duration of tilt
(average 8 min) in comparison with the half-life of ad-
renomedullin (20 min) might have attenuated a tilt-induced
decrease in the plasma concentration of this peptide. As in
our study, tilt had no influence on plasma ANF in healthy
individuals [38].
In theory a reduction in circulating adrenomedullin
could participate in the cardiovascular response to fluid
removal. In other words, the decrease in plasma ad-
renomedullin in response to ultrafiltration could contribute
to the compensatory rise in vascular tone that occurs during
this maneuver. The fact that adrenomedullin changes
throughout ultrafiltration were unrelated to mean arterial
pressure changes and to neurohumoral factors that have an
established role in cardiovascular homeostasis would speak
against such a possibility. Although our data are in line with
recent infusion studies in humans showing that the plasma
concentrations observed in pathophysiological conditions
Fig. 2. Adrenonemedullin and atrial
natriuretic factor (ANF) response to tilt in
healthy subjects. The mean arterial pressures
(MAP) and heart rates are shown. Data
represent mean 6 SEM.
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do not influence arterial pressure [33], the possibility
remains that plasma concentration does not reflect changes
at the tissue level and that adrenomedullin influences
vascular tone only by local mechanisms, that is, by acting in
close proximity of the secretion site. This possibility should
be explored in specifically designed intervention studies
using adrenomedullin antagonists.
In conclusion, plasma adrenomedullin is markedly raised
in uremic patients on hemodialysis, which indicates that the
kidney has a major role in the clearance of this peptide.
However, the fall in plasma adrenomedullin after isolated
UF suggests that the plasma concentration of this peptide is
dependent in part on the body fluid volume status. Whether
adrenomedullin participates in the counter-regulatory re-
sponse to fluid subtraction in uremic patients or not
remains to be explored by specific antagonists of this
substance.
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